Acquired hemophilia A

MONDO:0035735

An acquired form of hemophilia A, resulting in spontaneous bleeding in individuals with no history of bleeding disorders. It is believed to be caused by spontaneous inhibition of clotting factor VIII by autoantibodies, and is usually associated with other autoimmune conditions.

Also known as: AHA

18 clinical trials for this condition and its sub-types, 6 tagged with Acquired hemophilia A itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Acquired hemophilia (8)

Including sub-types (18) Tagged with Acquired hemophilia A (6)

Trials to join now! 2 Not yet recruiting 2 Not yet finished but already full! 1 Completed 1

New hope for rare bleeding disorder: emicizumab trial launches

Disease control Ongoing

This phase 2 trial tests the drug emicizumab (Hemlibra) as a regular injection to prevent bleeding in 51 adults with acquired hemophilia A, a rare condition where the immune system attacks clotting factors. Participants receive two loading doses then weekly shots, along with stan…

Phase 2 • Sponsor: University of Washington • Aim: Disease control

Last updated Jun 27, 2026 07:56 UTC

Acquired hemophilia A

Where it sits in the disease tree

New hope for rare bleeding disorder: emicizumab trial launches